fda glp-1 compounding warning october 2025 Warns Companies Over Compounded Retatrutide: What Healthcare Providers Should Know FDA is short-sighted on compounding

The FDA-approved label for Vyleesi reports that about 40 percent of patients experience nausea, and a meaningful percentage of patients either need anti-nausea medication or stop treatment because of it

Because healing isnt one-size-fits-all

Addiction/mental health A study of more than 2 million people with diabetes taking the popular weight-loss drugs found the medications were associated with reduced risks of seizures and addiction to substances such as alcohol, cannabis, stimulants and opioids

[7] Gangwisch et al., (2020) High glycemic index and glycemic load diets as risk factors for insomnia: analyses from the Womens Health Initiative, The American Journal of Clinical Nutrition, Volume 111, Issue 2, Pages 429-439, ISSN 0002-9165, nqz275